Pulmonary hypertension in patients with sarcoidosis: A single-center experience.
Journal
Anatolian journal of cardiology
ISSN: 2149-2271
Titre abrégé: Anatol J Cardiol
Pays: Turkey
ID NLM: 101652981
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
16
10
2021
Statut:
ppublish
Résumé
Sarcoidosis is a systemic granulomatous disease rarely complicated by pulmonary hypertension (PH). The prevalence of PH in sarcoidosis is unclear and has differences between ethnic groups. This study aimed to investigate the prevalence and predictors of PH in a Turkish cohort. The study included 55 patients with biopsy-proven sarcoidosis in a single center. All patients underwent detailed transthoracic echocardiography (TTE) to assess the probability of PH as recommended. Right heart catheterization (RHC) was performed for patients with intermediate-high risk of PH. Patients with mean pulmonary artery pressure >20 mm Hg by RHC were defined as PH. Demographic and clinical characteristics, laboratory data, spirometry, 6-min walk test, and TTE were compared between low and intermediate-high risk PH groups. The probability of PH was low with 47 patients. Eight patients had intermediate-high probability of PH, and two of them refused to undergo RHC. Of six intermediate-high probability patients, three had PH, and all of them had post-precapillary PH. The prevalence of PH in sarcoidosis was 5.5% (3/55). Six-minute walk distance (6 MWD) and diastolic parameters (E/A ratio, E' wave, and left atrial volume) were significantly lower, and New York Heart association class and N-terminal probrain natriuretic peptide (NT-proBNP) level were higher in intermediate-high risk PH patients compared with low-risk PH patients. The frequency of PH in sarcoidosis was 5.5% in a Turkish cohort. NT-proBNP, 6 MWD, diastolic function parameters, and myocardial strain parameters can be useful predictors of PH in patients with sarcoidosis, besides known echocardiographic parameters.
Identifiants
pubmed: 33382054
doi: 10.14744/AnatolJCardiol.2020.88054
pmc: PMC7803809
doi:
Substances chimiques
Peptide Fragments
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-41Références
J Am Soc Echocardiogr. 2015 Feb;28(2):183-93
pubmed: 25623220
Breathe (Sheff). 2016 Mar;12(1):43-9
pubmed: 27066136
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Clin Chest Med. 2007 Dec;28(4):717-33, vi
pubmed: 17967290
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Curr Hypertens Rep. 2018 Oct 5;20(12):99
pubmed: 30291516
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Chest. 2013 Jul;144(1):169-176
pubmed: 23348820
Adv Exp Med Biol. 2013;755:299-305
pubmed: 22826080
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Sarcoidosis Vasc Diffuse Lung Dis. 2016 Dec 23;33(4):317-320
pubmed: 28079843
Ann Thorac Med. 2010 Apr;5(2):86-91
pubmed: 20582173
Eur Respir J. 2019 Oct 31;54(4):
pubmed: 31320453
Eur J Echocardiogr. 2010 Dec;11(10):809-13
pubmed: 20513700
Eur Respir J. 2005 May;25(5):783-8
pubmed: 15863633
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):66-73
pubmed: 33093770
Lung. 2015 Oct;193(5):669-75
pubmed: 25990683